Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Debt / NOTE 1.000% 9/1
-
Market price (% of par)
-
94.06%
-
Total 13F principal
-
$1,012,540,800
-
Principal change
-
+$42,768,100
-
Total reported market value
-
$955,060,150
-
Number of holders
-
69
-
Value change
-
+$37,637,775
-
Number of buys
-
31
-
Number of sells
-
32
Institutional Holders of ALNYLAM PHARMACEUTICALS INC - NOTE 1.000% 9/1 as of Q1 2024
As of 31 Mar 2024,
ALNYLAM PHARMACEUTICALS INC - NOTE 1.000% 9/1 was held by
69 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$1,012,540,800
in principal (par value) of the bond.
The largest 10 bondholders included
Voya Investment Management LLC, Linden Advisors LP, UBS ASSET MANAGEMENT AMERICAS LLC, LAZARD ASSET MANAGEMENT LLC, Calamos Advisors LLC, Invesco Ltd., ADVENT CAPITAL MANAGEMENT /DE/, Opti Capital Management, LP, Aequim Alternative Investments LP, and STEELHEAD PARTNERS LLC.
This page lists
69
institutional bondholders reporting positions
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.